PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

Important study authored by Domino supports PCI’s Serialization and Aggregation activities.

Philadelphia, PA — September 20, 2017  Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities.  The study was executed to ensure no migration into drug product contained within HDPE bottles with directly applied codes.  Domino is an industry leader in coding and printing technologies operating in over 120 countries worldwide, and one of the key providers of coding technologies to PCI across its global supply network.

The white paper details PCI’s joint development with Domino to analyze potential leachability of coding inks used in the application of Serialized codes directly on HDPE bottles.  In the process of Aggregation in Serialization technologies, particularly for high speed bottling lines, it is common industry practice to utilize a second ‘helper’ code, often applied to the bottom of the bottle. Those helper codes are then digitally married to Serialized codes applied to labels on the side of the bottle and assist in line-of-sight verification in the commissioning and Aggregation process. The process of Aggregation establishes a parent-child relationship with the unit of sale and its ancillary packaging, providing numerous benefits in the supply chain.  The leachability study was commissioned to ensure proper usage of Domino-supplied inks and compliance with industry requirements in the prevention of ink migration and potential to affect drug product.

The study analyzes several ink types, including both visible black inks as well as invisible fluorescent ink used with ultraviolet (UV) inspection technologies.

PCI’s Ray Hook, Global Serialization Manager, commented: “We collaborated with Domino on this study due to their expertise and global capability for applications like this.  As we have progressed our Serialization strategy across our global supply network, it was critical that we identified methods that ensured product safety and security for our clients and the patients using these medicines.  Domino provided us with the assurance that we were following industry best practices as we further developed our capability with large scale aggregation activity.”

The study was a key precursor in PCI’s Serialization preparation activities. In February this year, PCI announced a significant capital investment in Serialization capability expansion.  The multimillion dollar investment effectively triples PCI’s Serialization capacity in advance of US and EU deadline requirements, with more than 80 installations across PCI’s global supply network.  PCI has been providing commercially Serialized drug product to domestic and emerging markets for over five years and is well positioned to support global strategic Serialization and anti-counterfeiting initiatives for its clients.

For more information or to download the Domino white paper, please visit: https://www1.domino-printing.com/en-us/white-papers/domino-and-pci-address-the-issue-of-ink-leachability  




About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

About Domino
As the leading business within Domino Printing Sciences plc, Domino is an autonomous division within Brother Industries. Founded in 1978, Domino has established a global reputation for the development and manufacture of coding, marking, printing technologies, aftermarket products and customer service. Today Domino offers a portfolio of end-to-end coding solutions designed to satisfy the compliance and productivity requirements of manufacturers including inkjet, laser, print and apply and thermal transfer overprinting technologies for application of variable and authentication data, bar codes and unique traceability codes onto product and packaging across many industrial sectors including food, beverage, pharmaceutical and industrial. Domino employs 2,600 people worldwide working with more than 120 countries through a global network of 25 subsidiary offices and over 200 distributors. Domino has manufacturing facilities in China, Germany, India, Sweden, Switzerland, United Kingdom and United States. For further information, please visit domino-na.com.



Contact for PCI

Remarkable Content
Chantel Richman 
Tel: +44 (0) 203 697 7657
Email: chantel.richman@remarkablegroup.co.uk 

Carrie Lowe at 
Tel: +44 (0) 1962 853 913 
Email: carrie.lowe@remarkablegroup.co.uk  

Contact for Domino
Tara L. Abbott
Marketing Manager
Domino North America
Tel: +1 905 901 1621
Email: Tara.abbott@domino-na.com

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: